We understand and support the need for increased disclosure of clinical trial data, and we continue to work with the Association of the British Pharmaceutical Industry (ABPI) on this important topic to ensure that any emerging regulations will result in benefits for everyone engaged in clinical research and patient care.
Since the publication of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Joint Position on the Disclosure of Clinical Trial Information, Napp has complied with the requirements to register and publish the outcomes of all trials that we have sponsored and that have been carried out in patients. Where possible, we publish data through peer-reviewed journals, but if this is not possible, we will share the data through a clinical trials registry, such as www.clinicaltrials.gov, www.clinicaltrialsregister.eu or here on our website.
Further information on Napp sponsored studies
The studies listed below were sponsored by Napp Pharmaceuticals Limited and started and/or completed after the publication of the IFPMA Joint Position on the Disclosure of Clinical Trials; information about these trials can be accessed by clicking on the links. Please note that we are providing these links for information only; this information must not be seen as a replacement for advice from a qualified healthcare professional. If prescribing Napp’s medicines, healthcare professionals must refer to the approved Summaries of Product Characteristics and not to the information contained in these studies.
Information about studies sponsored by our independently associated company, Mundipharma Research Limited, is available via their website. If you are searching for other clinical studies involving our medicines, they may be available by searching for the medicine name on www.clinicaltrials.gov, or you can contact our Medical Information Team for advice.
Comparison of oxycodone/naloxone and codeine/paracetamol in the treatment of moderate to severe chronic low back pain due to osteoarthritis.
Clinical study synopsis
A comparison of prolonged release oxycodone taken in combination with gabapentin with placebo in combination with gabapentin for the treatment of moderate to severe neuropathic pain in patients with diabetes.
Clinical study synopsis Peer reviewed publication